The startup develops antibody radiopharmaceuticals specifically targeting solid tumors, utilizing patented antibodies to enhance the precision of cancer treatment. This approach provides patients with more effective and safer therapeutic options compared to conventional cancer therapies.
Funding
$15M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many solid tumors, such as prostate, pancreatic, bladder, glioblastoma, esophageal, lung, and ovarian cancers, lack effective targeted therapies, leading to poor patient outcomes and significant unmet medical needs. Existing treatments often fail due to limited specificity, resulting in damage to healthy tissues and severe side effects.
Solution
GlyTherix is developing a novel approach to cancer treatment using targeted radiopharmaceuticals that precisely deliver radiation to solid tumors while sparing healthy tissue. Their patented antibodies, including Miltuximab and Glytuzumab, target Glypican-1 (GPC-1), a protein overexpressed in various aggressive cancers but not detectable in normal adult tissues. By labeling these antibodies with radioisotopes such as Lutetium-177, Actinium-225, and Zirconium-89, GlyTherix aims to create theranostic agents for both imaging and therapy, enabling personalized treatment strategies and improved patient outcomes. Their lead candidate, Miltuximab, has completed a Phase-1 trial demonstrating safety and tumor-targeting capabilities, and is advancing towards Phase 1b and Phase 2 trials.
Target Audience
The primary target audience includes patients with solid tumors expressing Glypican-1, such as prostate, pancreatic, bladder, glioblastoma, esophageal, lung, and ovarian cancers, as well as oncologists and nuclear medicine physicians seeking more effective and targeted treatment options.
Features
- Miltuximab: A first-in-human anti-GPC-1 monoclonal antibody demonstrating safety and tumor targeting in clinical trials.
- Glytuzumab: A humanized version of Miltuximab currently undergoing lead optimization for enhanced therapeutic potential.
- Targeted Radiotherapy: Utilizes radioisotopes (Lutetium-177, Actinium-225, Zirconium-89) to deliver localized radiation directly to GPC-1 expressing tumor cells.
- Theranostic Approach: Enables patient selection via PET imaging using Zirconium-89 labeled Miltuximab, followed by targeted therapy with Lutetium-177 labeled Miltuximab.
- Intellectual Property: Strong patent protection covering both the anti-GPC-1 antibody and the GPC-1 antigen itself.
- GMP Manufacturing: High-yield, GMP-compliant primary cell bank established for Miltuximab production.
- Research Collaborations: Partnerships with leading universities and research institutions to advance radiopharmaceutical development and clinical trials.